These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 2663256)

  • 21. The mechanisms of penicillamine, trientine, and zinc in the treatment of Wilson's disease.
    Yarze JC
    Am J Gastroenterol; 1995 Jun; 90(6):1026. PubMed ID: 7771405
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine).
    Dubois RS; Rodgerson DO; Hambidge KM
    J Pediatr Gastroenterol Nutr; 1990 Jan; 10(1):77-81. PubMed ID: 2324883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The treatment of Wilson's disease in paediatrics: oral zinc therapy versus penicillamine.
    Cossack ZT; Bouquet J
    Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 7():514-7. PubMed ID: 3776618
    [No Abstract]   [Full Text] [Related]  

  • 24. A copper for your thoughts.
    Coates RA
    J Insur Med; 2012; 43(2):112-5. PubMed ID: 22876415
    [No Abstract]   [Full Text] [Related]  

  • 25. Improvement of cardiovascular autonomic dysfunction following anti-copper therapy in Wilson's disease.
    Deguchi K; Sasaki I; Touge T; Tsukaguchi M; Ikeda K; Shimamura M; Urai Y; Watanabe S; Takeuchi H; Kuriyama S
    J Neurol; 2005 Apr; 252(4):495-7. PubMed ID: 15726258
    [No Abstract]   [Full Text] [Related]  

  • 26. Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration).
    Hoogenraad TU; Koevoet R; de Ruyter Korver EG
    Eur Neurol; 1979; 18(3):205-11. PubMed ID: 477692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Wilson's disease (hepatolenticular degeneration) with penicillamine and low-copper diet.
    Goldstein NP; Tauxe WN; McCall JT; Gross JB; Randall RV
    Trans Am Neurol Assoc; 1969; 94():34-7. PubMed ID: 5374484
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine.
    Brewer GJ; Askari F; Dick RB; Sitterly J; Fink JK; Carlson M; Kluin KJ; Lorincz MT
    Transl Res; 2009 Aug; 154(2):70-7. PubMed ID: 19595438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.
    Appenzeller-Herzog C; Mathes T; Heeres MLS; Weiss KH; Houwen RHJ; Ewald H
    Liver Int; 2019 Nov; 39(11):2136-2152. PubMed ID: 31206982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Control of the therapeutic prevention of copper uptake in the liver in Wilson's disease following oral administration of 64Cu].
    Günther K; Siegemund R; Lössner J; Kühn HJ
    Radiobiol Radiother (Berl); 1988; 29(2):226-9. PubMed ID: 3399664
    [No Abstract]   [Full Text] [Related]  

  • 31. Penicillamine in Wilson's disease.
    Danks DM
    Lancet; 1982 Aug; 2(8295):435-6. PubMed ID: 6124819
    [No Abstract]   [Full Text] [Related]  

  • 32. [Wilson's disease].
    Cramarossa L; D'Angelo D; D'Ascanio I; Ferri GB; Piane E
    Recenti Prog Med; 1992 May; 83(5):255-61. PubMed ID: 1439104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.
    Brewer GJ
    J Cell Mol Med; 2003; 7(1):11-20. PubMed ID: 12767257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Wilsons disease].
    Mareček Z; Brůha R
    Vnitr Lek; 2013 Jul; 59(7):578-83. PubMed ID: 23909262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wilson disease.
    El-Youssef M
    Mayo Clin Proc; 2003 Sep; 78(9):1126-36. PubMed ID: 12962167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [On hepatolenticular degeneration (Wilson's disease). 3. Hepatic localization of Cu64: scintigraphic and dynamic study before and after treatment with BAL and D-penicillamine].
    D'Addabbo A; Damato VD; Germinario L; Campanella G; Boccuni N
    Acta Neurol (Napoli); 1971; 26(4):436-48. PubMed ID: 5132825
    [No Abstract]   [Full Text] [Related]  

  • 37. Interactions of zinc and molybdenum with copper in therapy of Wilson's disease.
    Brewer GJ
    Nutrition; 1995; 11(1 Suppl):114-6. PubMed ID: 7749256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can Wilson's disease patients be decoppered?
    Mason J; McQuaid A; Pheiffer H
    Lancet; 1989 Jun; 1(8652):1455. PubMed ID: 2567467
    [No Abstract]   [Full Text] [Related]  

  • 40. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
    Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
    Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.